263. 脳腱黄色腫症 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 8 / 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 3

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Blinded cdca 250 MG TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States
Blood tests
   Sheba Medical Center
      2010   -   NCT01613898   Israel
Cdca weight-based dose TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States
Chenodeoxycholic acid
   Department of Veterans Affairs
      1999   -   NCT00018694   United States
   Fujimoto Pharmaceutical Corporation
      2020   Phase 3   JPRN-jRCT2080225062   Japan
   Leadiant Biosciences, Inc.
      2024   Phase 3   NCT06260748   Israel
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004346   United States
Chenodeoxycholic acid leadiant
   Humanis Saglik Anonim Sirketi
      2022   Phase 1   NCT06180057   Jordan
Lovastatin
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004346   United States
Mutation analysis
   TRPHARM
      2019   -   NCT04218006   Turkey
OPEN-label cdca 250 MG TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States
Rescue medication cdca 250 MG TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States